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Lung cancer is the top cancer killer worldwide with high mortality rate. Majority
belong to non-small cell lung cancers (NSCLCs). The epidermal growth factor receptor
(EGFR) has been broadly explored as a drug target for therapy. However, the drug
responses are not durable due to the acquired resistance. MicroRNAs (miRNAs) are
small non-coding and endogenous molecules that can inhibit mRNA translation initiation
and degrade mRNAs. We wonder if some downstream molecules shared by EGFR and
the other tyrosine kinase receptors (TKRs) further transduce the signals alternatively,
and some miRNAs play the key roles in affecting the expression of these downstream
molecules. In this study, we investigated the mRNA:miRNA associations for the direct
EGFR downstream molecules in the EGFR signaling pathway shared with the other
TKRs, including c-MET (hepatocyte growth factor receptor), Ron (a protein tyrosine
kinase related to c-MET), PDGFR (platelet-derived growth factor receptor), and IGF-1R
(insulin-like growth factor receptor-1). The multiple linear regression and support vector
regression (SVR) models were used to discover the statistically significant and the best
weighted miRNAs regulating the mRNAs of these downstream molecules. These two
models revealed the similar mRNA:miRNA associations. It was found that the miRNAs
significantly affecting the mRNA expressions in the multiple regression model were also
those with the largest weights in the SVR model. To conclude, we effectively identified a
list of meaningful mRNA:miRNA associations: phospholipase C, gamma 1 (PLCG1) with
miR-34a, phosphoinositide-3-kinase, regulatory subunit 2 (PIK3R2) with miR-30a-5p,
growth factor receptor-bound protein 2 (GRB2) with miR-27a, and Janus kinase 1 (JAK1)
with miR-302b and miR-520e. These associations could make great contributions to
explore new mechanism in NSCLCs. These candidate miRNAs may be regarded as the
potential drug targets for treating NSCLCs with acquired drug resistance.
Keywords: microRNA, EGFR, alternative tyrosine kinase receptors, multiple linear regression, support vector
regression model, non-small cell lung cancer
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INTRODUCTION
Lung cancer is the top cancer killer worldwide with high
mortality rate (Wang et al., 2015). Over 80% of cases belong
to non-small cell lung cancer (NSCLC) with the continuously
rising incidence rate every year (Al-Saleh et al., 2012). The 5-
year overall survival rate of NSCLC is very low, due to lack of
the effective diagnosis and treatment methods (Indovina et al.,
2011). Hence, novel and effective targets are needed urgently
for cancer diagnosis and therapy. The epidermal growth factor
receptor (EGFR) has been broadly explored as a drug target
for treatment, since it is overexpressed in various tumors, such
as breast and lung carcinomas (Kim et al., 2001; Camp et al.,
2005). The receptor tyrosine kinase inhibitors (TKIs), including
Gefitinib and Erlotinib, are small molecules that inhibit EGFR
phosphorylation, receptor activation and the subsequent signal
transduction (Camp et al., 2005). However, the drug responses
are not durable due to the acquired resistance. The secondary
mutation in EGFR exon 20 (T790M) was found in approximately
50% of resistant tumors (Zhang et al., 2012; Kumarakulasinghe
et al., 2015). Besides the mutation, activation of alternative
tyrosine kinase receptors (TKRs) sharing similar downstream
pathways with EGFR has been proved to be one of the multiple
resistance mechanisms, including c-MET (hepatocyte growth
factor receptor), Ron (a protein tyrosine kinase related to c-
MET), PDGFR (platelet-derived growth factor receptor), and
IGF-1R (insulin-like growth factor receptor-1) (Camp et al.,
2005).
MicroRNAs (miRNAs) are small non-coding and endogenous
molecules with 19–22 nucleotides, which inhibit mRNA
translation initiation and degrade mRNAs (Zandberga et al.,
2013). MiRNAs play a vital role in cancer development
and progression by regulating the signaling circuits and the
dysregulation in a cell (Zandberga et al., 2013). MiRNAs are
regarded as the important biomarkers for cancer, since their
expression profiles are mostly tissue- specific and able to signify
human cancers (Lu et al., 2005). It has been found that nearly all
the cancers have different miRNA expression profiles compared
with the adjacent normal tissues, especially in lung and breast
cancers (Zhang and Farwell, 2008). MiRNAs were also reported
to be related to tumor invasion and metastasis (Ma et al., 2007).
Let-7 is a notable miRNA in lung cancer, which is involved in the
pathogenesis and significantly decreased in lung cancer tissues
(Zhang and Farwell, 2008). MiR-128b directly targets EGFR, and
its expression is positively correlated with clinical response and
survival for Gefitinib treatment in lung cancer (Weiss et al., 2008;
Lin et al., 2010). Multiple genes in the EGFR signaling pathway
are targeted by miR-7, such as EGFR and protein kinase B (Akt)
(Webster et al., 2009). MiRNAs are vital in the EGFR signaling
pathway, and remarkable for potential drug discovery.
Due to the critical regulatory role of miRNAs in the
cellular processes and disease pathology, many prediction
algorithms have beenmade publicly online to predict the putative
mRNA:miRNA pairs based on the sequence analysis, such as
TargetScan and PicTar (Krek et al., 2005; Agarwal et al., 2015).
However, the identification of the regulatory miRNA and mRNA
pairs is still a major challenge, because a single miRNA may
target several mRNAs, and multiple miRNAs may co-regulate
the same mRNA (Jayaswal et al., 2011). Moreover, the prediction
databases do not take into account miRNA/mRNA expression
levels. The regulatory effects of miRNAs may vary in different
situations. In other words, different cancer cells may have
different regulatory miRNAs. Hence, Microarray profiling of
miRNAs and mRNAs has been widely used to analyze the
whole genome to further explore their regulatory effects. Both
mRNA and miRNA expression levels can be quantified using
microarray technology.We introducedmultiple linear regression
and support vector regression models to identify the regulatory
effects of multiple miRNAs on the same mRNAs by analyzing the
microarray data.
The aim of this study was to identify the direct downstream
proteins of EGFR in the EGFR signaling pathway shared with
the other TKRs (c-MET, Ron, PDGFR, and IGF-1R), and to
further explore the candidate miRNAs affecting the mRNA
expressions of these proteins. We hypothesize that there are
some important downstream proteins shared by EGFR and the
other TKRs, possibly leading to the resistance of EGFR TKIs,
and some key miRNAs targeting these proteins are dysregulated
in NSCLCs. In order to support our hypotheses, we proposed
a novel mRNA:miRNA association identification approach that
consists of two steps. The first step involved the identification of
putative miRNA and mRNA pairs from the prediction databases.
The second step is to identify the statistically significant and the
best weighted miRNAs for the mRNAs of the shared downstream
molecules using multiple linear regression and support vector
regression models based on the microarray expression profiles.
Our approach could reduce the intricate interactions between
miRNAs and mRNAs to a few meaningful mRNA:miRNA
associations, which facilitates the subsequent biological analysis
and more efficient experimental validation. These candidate
miRNAsmay be served as potential drug targets for the treatment
of NSCLCs with drug resistance.
METHODS
Microarray Expression Data
In this study, the microarray datasets GSE51852 and GSE51853
for mRNAs and miRNAs were collected from Gene Expression
Omnibus (GEO) repository database (Arima et al., 2014). Both
collected mRNA and miRNA data have been normalized. The
subjects were recruited in Japan. The researchers analyzed the
global expression profiles of miRNAs and the target mRNAs
based on a systems biology-based approach using a Bayesian
network and non-parametric regression to identify the functional
gene regulatory circuitry involved in the lung adenocarcinoma
(Arima et al., 2014). We chose 46 subtype NSCLC specimens for
the analysis of miRNA and mRNA expression profiles obtained
from the same patients (Table S1). In the microarray data, each
mRNA is usually interrogated by more than one probes. We took
the average of the multiple probes for the same mRNA (Breslin
et al., 2005; Kapp et al., 2006).
MiRNA Profiling for the Shared
Downstream Molecules
The directly interacting downstream molecules of EGFR in
the EGFR signaling pathway were selected using MetaCore R©
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from GeneGo Inc. MetaCore R© incorporates the online validated
interactions from researchers to the pathways. The signaling
pathways of the other TKRs (c-MET, Ron, PDGFR, and IGF-1R)
were also considered to select the shared downstream molecules.
The miRNAs regulating the mRNAs of the shared downstream
molecules were selected using the representative resources:
MicroCosm-Targets (Griffiths-Jones et al., 2008), TargetScan
(Agarwal et al., 2015), miRanda-mirSVR (Betel et al., 2010),
miRDB (Wong and Wang, 2015), and PicTar (Krek et al., 2005).
We searched for the miRNAs targeting each mRNA using these
databases, and selected the miRNAs with the support of at least
two out of the five databases. We further obtained the expression
levels of these mRNAs and miRNAs from the microarray data.
This set of mRNAs and miRNAs, as well as their expression
profiles were considered for multiple regression analysis.
Identification of Statistically Significant
miRNAs from Multiple Linear Regression
Model
After obtaining the expression of the selected mRNAs and
miRNAs, we performed the multiple linear regression analysis to
explore the relationship of each mRNA with the corresponding
miRNAs (Wang et al., 2014a,b). Since multiple miRNAs may
simultaneously target one mRNA during the post-transcriptional
process, and the effect of each miRNA may be different, multiple
linear regression analysis was applied to explore their relationship
in formula (1):
y = a0 + a1·x1 + a2·x2 + . . .+ an·xn (1)
where y was the expression level of an mRNA; x1, x2, ... and
xn were the expression profiles of the corresponding miRNAs.
The parameters, a0, a1, a2, ... and an, represented the regression
constant and coefficients, respectively.
Support Vector Regression (SVR) Model
Furthermore, support vector regression (SVR) machine (Smola
and Vapnik, 1997; Gunn, 1998) was used to model the
relationship of the selected mRNAs and multiple miRNAs. This
problem was considered as approximating the set of data,
(
y1, x1
)
, . . .
(
ym, xm
)
, x ∈ Rn, y ∈ R,
with a linear function
f (x,w) = w·x+ b (2)
where f was an output variable, which denoted the expression
level of mRNA, x was an input feature vector, which represented
the expression profiles of multiple miRNAs, andw and bwere the
linear regression coefficients. To obtain the model, the error was
measured based on the ǫ−insensitivity loss function defined by
L
(
y, f (x,w)
)
=
∣∣y− f (x,w)∣∣ =
{
0, if
∣∣y− f (x,w)∣∣ ≤ ǫ∣∣y− f (x,w)∣∣− ǫ, otherwise
(3)
The optimal regression function can be obtained by minimizing
Rw, L =
1
2
||w||2 + C
(∑m
i= 1
εi +
∑m
i= 1
ε∗i
)
, (4)
under constraints
yi −
(
wxi + b
)
≤ ǫ + εi(
wxi + b
)
− yi ≤ ǫ + ε
∗
i
εi ≥ 0
ε∗i ≥ 0
where
∣∣y− f (x,w)∣∣− ǫ = ε for the data above ǫ tube
∣∣y− f (x,w)∣∣− ǫ = ε∗ for the data below ǫ tube
In formula (4), the first term measured the confidence interval,
the second term was used to measure the empirical risk, and C
was applied to control the magnitude of approximation errors.
In the simulation, C was equal to the difference between the
maximum and the minimum of mRNA expression profiles.
RESULTS
Selection of Direct Downstream Molecules
of EGFR Shared with the Other TKRs and
the Corresponding miRNAs
The EGFR signaling pathway was downloaded fromMetaCore R©,
as shown in Figure 1. There were 11 key directly interacting
downstream molecules of EGFR: phospholipase C, gamma 1
(PLCG1), phosphoinositide-3-kinase, regulatory subunit 1 & 2
(PIK3R1/2), Cbl proto-oncogene, E3 ubiquitin protein ligase
(CBL), growth factor receptor-bound protein 2 (GRB2), Src
homology 2 domain containing transforming protein 1 (SHC1),
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
(avian) (SRC), Janus kinase 1 & 2 (JAK1/2), NCK adaptor
protein 1 (NCK1), and protein tyrosine kinase 2 (PTK2). In
total, there were 8 out of 11 downstream molecules shared by
EGFR and the other TKRs according to their signaling pathways
from MetaCore R© (Table 1, Figure 1). MiRNAs regulating these
mRNAs were obtained from five miRNA prediction databases.
The candidate miRNAs were selected, as shown in Table S2.
The expression profiles of the mRNAs and the corresponding
miRNAs were further extracted from the microarray datasets for
regression analysis (Table S1).
Multiple Linear Regression Model to
Identify the Statistically Significant
miRNAs Regulating the Shared
Downstream Molecules
The associations of each mRNA transcript of the shared
downstream molecules with the corresponding miRNAs were
investigated by multiple linear regression model. This analysis
was performed using IBM SPSS and MATLAB. The results
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FIGURE 1 | EGFR signaling pathway modified from MetaCore®. The
downstream molecules shared with the other TKRs (c-MET, Ron, PDGFR, and
IGF-1R) were marked by arrowed lines with different colors.
TABLE 1 | Direct downstream molecules of EGFR shared with the other
TKRs.
Shared downstream molecules Shared with the other TKRs
PLCG1 c-MET, Ron, PDGFR
PIK3R1 c-MET, Ron, PDGFR, IGF-1R
PIK3R2 c-MET, Ron, PDGFR, IGF-1R
GRB2 c-MET, PDGFR, IGF-1R
SHC1 c-MET, PDGFR, IGF-1R
SRC PDGFR
JAK1 PDGFR
JAK2 PDGFR
demonstrated the significant miRNAs (p < 0.05): miR-34a
was negatively significantly associated with PLCG1, miR-30a-
5p was negatively significantly associated with PIK3R2, miR-27a
was negatively significantly associated with GRB2, miR-302b was
positively significantly associated with JAK1 and miR-520e was
negatively significantly associated with JAK1, as well as miR-
155 was positively significantly associated with JAK2 (Table 2).
Two directions were found for the mRNA:miRNA relationship:
negative and positive. The results revealed that somemRNAs had
only one significant miRNA, while, some mRNAs had more than
one significant miRNAs.
SVR Model to Determine the Best
Weighted miRNA(s)
Through the SVR model manipulation, the linear regression
coefficient of each miRNA was obtained, which represented the
weight of eachmiRNAmaking the contribution to the expression
levels of the target mRNAs. The results depicted (Figure 2): miR-
34a had the largest negative weight in the PLCG1 model, miR-
30a-5p had the largest negative weight in the PIK3R2 model,
miR-27a had the largest negative weight in the GRB2 model, as
TABLE 2 | Significant miRNAs targeting the shared downstream
molecules (p < 0.05).
mRNA Significant miRNAs
Positive (+) Negative (−)
PLCG1 miR-34a
PIK3R2 miR-30a-5p
GRB2 miR-27a
JAK1 miR-302b miR-520e
JAK2 miR-155
well as miR-302b had the largest positive weight and miR-520e
had the largest negative weight in the JAK1 model. The results
were consistent with the findings of the multiple linear regression
model that these best weighted miRNAs had the significant p-
values, and the signs of the weights were also the same, indicating
the same direction. A little bit difference was found in JAK2
model that miR-155 had the second largest positive weight.
The weight of miR-621 was the largest. In the multiple linear
regression model, the p-value for miR-621 was 0.057, nearly
significant. Possibly, enlarging the sample size could polish the
results. In order to prove the prediction efficiency of the SVR
model, we plotted the scatter diagrams for the expression levels of
the original mRNAs from the microarray data and the predicted
mRNAs based on the constructed SVR model (Figure 3). From
the results, we could demonstrate that the data points were
concentrated around the red line Y = X, which means that
the SVR method was capable of well modeling the relationship
between mRNAs and the multiple miRNAs.
DISCUSSION
In this study, we investigated the direct EGFR downstream
molecules in the EGFR signaling pathway shared with the other
TKRs that may affect the drug resistance (Table 1, Figure 1). The
statistically significant and the best weighted miRNAs regulating
the mRNAs of these shared downstream molecules were further
explored using the multiple linear regression and support vector
regression models (Table 2, Figure 2). Multiple linear regression
can obtain the linear regression equation to represent the
relationship between the mRNA and the multiple miRNAs by
minimizing the mean least square error. It can also indicate
the significance of each miRNA coefficient from the point of
statistical view. By contrast, SVR can model the associations
between mRNAs and miRNAs through maximizing regression
margin and minimizing error. The two introduced methods
found the similar mRNA:miRNA associations. The potential
miRNAs significantly affecting the expression of mRNAs from
multiple regression analysis were further identified through the
weights in the SVR model. Since one mRNA could be regulated
by more than one miRNAs, multiple regression analysis is
more suitable to simulate the in vivo environment and identity
the significant miRNAs. Furthermore, SVR method could well
model the associations between the mRNAs and the multiple
miRNAs from the results (Figure 3). Our approaches using in
Frontiers in Genetics | www.frontiersin.org 4 October 2016 | Volume 7 | Article 173
Wang et al. Associations of mRNA:miRNA in NSCLC
FIGURE 2 | Distribution of miRNA weights for the target mRNAs in the SVR model. The red dot indicated the best weighted miRNA(s).
silico analysis could demonstrate the important findings and
infer the biological meaning before performing the experimental
validation.
Our method could enable the identification of mRNAs that
were co-regulated by multiple significant miRNAs and those
that were targeted by only one significant miRNA, as well as
the direction of the relationship. Both positive and negative
relationships were found in our results (Table 2, Figure 2), such
as the positive association between JAK1 and miR-302b, and
the negative association between PLCG1 and miR-34a. Some
molecules had more than one significant miRNAs, e.g., JAK1.
Different interaction types may exist to affect the associations
between mRNAs and miRNAs. The direct binding of miRNAs
to the seed regions of mRNAs can influence the stability of
mRNAs and the translation process from mRNAs to proteins
(Androsavich et al., 2012). Since miRNA binding could degrade
the target mRNAs, negative associations will be possibly found.
Researchers have reported that some mRNAs may not be
degraded when miRNAs bind to the seed regions. The bindings
could lead to the accumulations of the inhibitedmRNAs (Franco-
Zorrilla et al., 2007; Ambs et al., 2008). This mechanism may
result in the positive relationship between mRNAs and miRNAs.
Moreover, the indirect interaction through the intermediators
between them could also generate the positive associations.
The presence of other activated TKRs can mimic the function
of EGFR by activating the shared signal transduction pathways
to promote cell survival (Camp et al., 2005). Downstream
molecule, phosphoinositide-3-kinase (PI3K), shared by both
EGFR and one of these TKRs IGF-1R has been reported to
affect the resistance to EGFR-TKIs (Camp et al., 2005). MiRNAs
play important roles in the EGFR signaling pathway, therefore,
they are remarkable for drug discovery in cancer therapy. To
investigate the relationship between miRNAs and drug resistance
makes the valuable contribution to improve the therapeutic
efficacy of cancer. Since not every protein is suitable for drug
target, specific manipulation of the undruggable proteins can
be realized through the corresponding miRNAs targeting the
mRNAs: miRNA inhibitors can upregulate one protein and
miRNA mimics can silence one gene (Schmidt, 2014). People
have tested a liposomal nanoparticle loaded with synthetic
miRNA-34a mimics (MRX34) that against cancer cells when
combined with the EGFR-TKI Erlotinib treatment (Bader, 2012;
Zhao et al., 2014). The additive or synergistic effects of miRNAs
together with another treatment provide a novel platform for
treating resistant cancer cells (Wu, 2010). MiR-15b and miR-16
in combination with chemotherapy can induce the sensitivity
of gastric cancer cells by inhibition of cyclin D1 (BCL1) (Zhao
et al., 2008). Consequently, inducing the cancer cell sensitivity by
miRNAs provides a novel approach for cancer treatment, at least
in vitro (Wu, 2010).
The candidate miRNAs discovered in our study have been
investigated in cancer research. MiR-34a has been identified as a
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FIGURE 3 | Scatter diagram for the expression levels of the original mRNAs from microarray data and the predicted mRNAs from SVR models. The red
line referred to Y = X to indicate the location of the data points.
novel prognostic marker in NSCLCs, making great contributions
for evaluating the recurrence risk of patients and providing
useful information for cancer treatment (Gallardo et al., 2009).
Other researchers found that miR-34a can significantly reduce
the tumor growth in an in vivo murine model and activate some
major proteins involved in the apoptosis process, which may act
as a suppressor of tumorigenesis (Welch et al., 2007; Tivnan et al.,
2011). It has been reported that miR-30a might function as a
metastasis suppressor by downregulating phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD) in
colorectal carcinoma to suppresses cell migration and invasion
(Zhong et al., 2013). MiR-27a plays an important role in the
regulation of drug resistance, indicating its potential property
for therapeutic strategy in cancer cell lines (Zhu et al., 2008).
MiR-155 has been explored as the well characterized signatures
for breast, colon and lung cancers (Volinia et al., 2006). To our
best knowledge, some of the identified miRNAs in our study have
limited information for NSCLC research in the literatures, which
may be the novel and important findings needed to be further
exploration.
In summary, our study introduced the mRNA:miRNA
multiple linear regression and SVR models to identify the
significant and the best weighted miRNAs regulating the shared
downstream molecules of EGFR and other TKRs that may
affect the drug resistance. These candidate miRNAs can be
regarded as the potential drug targets for NSCLC treatment,
or combined with Gefitinib and Erlotinib treatment. Several
methods have been established to identify the associations
between miRNAs and mRNAs. One of the widely used methods
is the application of gene set test (GST). In this method, the
first step is to select the putative miRNA-mRNA pairs using
the prediction databases. And then, the GST is performed to
get the significant mRNAs for a given miRNA based on the
microarray data (Subramanian et al., 2005; Efron and Tibshirani,
2007). Another method is the application of odds-ratio (OR)
statistic (Jayaswal et al., 2009). If the significant associations are
found between miRNA and its computationally predicted target
mRNAs according to microarray expression levels, the miRNA is
considered to have the regulatory function. These twomentioned
methods can only identify the individual regulatory miRNAs,
and ignore the behind biological meaning that multiple miRNAs
may co-regulate a target mRNA simultaneously. Jayaswal et al.
proposed a method to identify the mRNA:miRNA modules
(Jayaswal et al., 2011). Firstly, to identify the miRNA and
mRNA clusters using computationally predicted approach and
expression data. Secondly, to obtain the statistically significant
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associations between miRNA and mRNA clusters based on the
expression levels. This method only considers the significant
cluster pairs, and do not take into account the weight of the
multiple miRNAs on the same mRNAs. Our developed method
incorporated these factors, and could identify the statistically
significant and the best weighted miRNA(s) for a particular
mRNA.
In the future, we will collect more public datasets to
perform the similar analysis to polish our findings. Laboratory
experimental validation will be done to explore the true effects of
the identified miRNAs on drug resistance in NSCLCs, including
Polymerase chain reaction (PCR) and wester-blot. Furthermore,
knock-down of the other TKRs and the shared downstream
molecules, as well as miRNA mimics/inhibitors experiments will
be performed to support the hypothesis and the current findings.
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